NCT00117871

Brief Summary

The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks. A second purpose is to evaluate the safety of the drug.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2004

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 30, 2005

Completed
11 days until next milestone

First Posted

Study publicly available on registry

July 11, 2005

Completed
Last Updated

February 19, 2007

Status Verified

November 1, 2006

First QC Date

June 30, 2005

Last Update Submit

February 16, 2007

Conditions

Warts

Keywords

WartsAdultsCommon WartsResiquimod

Outcome Measures

Primary Outcomes (1)

  • Clearance of treated wart(s)

Secondary Outcomes (1)

  • Partial clearance of treated wart(s)

Interventions

ResiquimodDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of common warts
  • Two forms of birth control

You may not qualify if:

  • Pregnant or breast feeding
  • Other types of warts, ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Minnesota Clinical Study Center

Fridley, Minnesota, 55432, United States

Location

MeSH Terms

Conditions

Warts

Interventions

resiquimod

Condition Hierarchy (Ancestors)

Papillomavirus InfectionsDNA Virus InfectionsVirus DiseasesInfectionsSkin Diseases, ViralTumor Virus InfectionsSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
SINGLE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 30, 2005

First Posted

July 11, 2005

Study Start

October 1, 2004

Last Updated

February 19, 2007

Record last verified: 2006-11

Locations

US(1)